Peptides for skin — what research has explored for collagen, glow, and aging

The skin-care industry has had peptides in its formulations for decades. Most of what you find on the ingredient list of a premium moisturizer is a cosmetic peptide — a signal molecule chosen for its ability to mimic or stimulate a biological process that supports skin structure. The science behind many of these is more developed than the science behind many compounds discussed in other peptide categories. That does not mean every claim is warranted. It means the landscape is old enough to have real data in some places, and real disappointment in others, and that the job here is to distinguish between them.

Skin aging has several simultaneous mechanisms. Collagen — the structural protein that gives skin its tensile strength and volume — declines in both quantity and quality after the mid-twenties, with accelerated loss in the decade after menopause in women. Elastin, which gives skin its ability to snap back, degrades and is not efficiently replaced. The extracellular matrix — the scaffolding in which skin cells live — becomes less organized. Vascularization in the dermis decreases, reducing the delivery of nutrients and the removal of waste. Glycosaminoglycans like hyaluronic acid, which keep the matrix hydrated, decline. UV exposure accelerates all of these processes through oxidative stress and matrix metalloproteinase activation. The result is not one thing going wrong — it is multiple systems running down at the same time. The peptide landscape for skin reflects this complexity: different compounds interact with different parts of the problem.

GHK-Cu — glycyl-L-histidyl-L-lysine copper — is the compound with the deepest evidence base in this space. It is a naturally occurring tripeptide that was first identified in human plasma and later found to be present in higher concentrations in wound healing environments. Loren Pickart, who identified the peptide in the 1970s, spent decades documenting its biological effects, which turned out to be surprisingly broad: GHK-Cu promotes collagen and elastin synthesis, stimulates glycosaminoglycan production, activates metalloproteinases and their inhibitors in a remodeling pattern rather than a degradation pattern, promotes angiogenesis, and has antioxidant effects. In the context of skin specifically, topical GHK-Cu has been studied in clinical trials demonstrating measurable improvements in skin density, fine lines, and laxity. These are not in-vitro or animal findings — there are controlled studies with histological and mechanical endpoints in human subjects. Procter and Gamble licensed GHK-Cu research and developed it into commercial skincare formulations; SkinCeuticals, Skin Biology, and multiple other companies have built products around it. The compound's 5-alpha reductase modulation effects — a finding that emerged from hair research — are secondary to its primary connective tissue effects in the skin context. The evidence for topical GHK-Cu on skin aging outcomes is among the best in the peptide skin landscape.

PAL-GHK is a lipopeptide derivative of GHK — the palmitoyl modification attaches a fatty acid chain to the peptide, which dramatically improves its penetration through the lipid barrier of the stratum corneum. Topical peptides face a fundamental bioavailability challenge: the skin is designed to keep things out, and larger, more polar molecules do not penetrate efficiently. The palmitoyl modification is one strategy the cosmetic industry uses to address this — Palmitoyl Pentapeptide-4 (Matrixyl), palmitoyl tripeptide-1 (PAL-GHK), and palmitoyl tripeptide-7 are all variants of this approach. PAL-GHK retains the collagen-stimulating properties of GHK in a form better suited to topical delivery. The research on PAL-GHK and its relatives is largely industry-funded, which is worth acknowledging, but some studies show genuine dermal collagen changes on biopsy.

Snap-8 — octapeptide-2 — is a topical cosmetic peptide marketed as a topical alternative to botulinum toxin, based on its claimed ability to inhibit the SNARE protein complex at the neuromuscular junction and thereby reduce the micro-contractions that deepen expression lines. The biology is plausible in outline; the clinical evidence for a meaningful anti-wrinkle effect from topical application is modest, given both the challenge of skin penetration and the question of whether the concentration achievable topically is sufficient to produce the claimed effect. It appears widely in premium formulations and has some clinical data, but the effect size is not comparable to botulinum toxin and should not be presented as though it were.

The systemic skin-support angle is where injectable approaches enter the picture, and where the evidence picture becomes more speculative. The GH-IGF-1 axis has documented effects on skin density and collagen content — IGF-1 stimulates fibroblast proliferation and collagen synthesis, and the well-documented skin thinning that accompanies growth hormone deficiency in adults is a meaningful data point. It follows that restoring GH pulse amplitude through compounds like sermorelin or the CJC/ipamorelin stack might have downstream effects on skin quality, and many clinicians and patients who use these compounds for other purposes report subjective improvements in skin texture. The human evidence for this specifically — controlled data isolating skin density changes as a function of GHRH or GHRP-mediated GH restoration — is limited. The mechanistic logic is sound; the clinical evidence is mostly observational and anecdotal.

Glutathione is the body's primary endogenous antioxidant, a tripeptide of glycine, cysteine, and glutamate that protects cells from oxidative damage and plays a role in skin brightness through its effects on melanin synthesis pathways. Intravenous and oral glutathione have been used and studied in contexts of skin brightening, particularly in Southeast Asia and among darker skin tone populations where even skin tone is a significant cosmetic concern. Some studies show effects on skin lightening and texture with intravenous glutathione supplementation; the evidence is mixed and the practice has safety considerations at high doses and via IV routes. Oral glutathione has poor bioavailability through direct supplementation, though precursor supplementation (N-acetylcysteine) is better studied. In the anti-aging context more broadly, glutathione is understood as a foundational antioxidant support rather than a primary skin-active compound.

NAD+ intersects with skin aging through its role in DNA repair — specifically through PARP enzymes and sirtuins — and through mitochondrial efficiency in skin cells. UV radiation depletes NAD+ in skin cells, impairing their DNA damage repair capacity and accelerating photoaging. The research interest in NAD+ for skin is real at the mechanistic level, though clinical evidence for skin-specific effects of NAD+ supplementation is not well-developed. It appears in skin aging discussions more as a cellular health foundational consideration than as a targeted skin compound.

Melanotan I and Melanotan II require careful placement in this landscape. They are synthetic analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) and were originally developed as potential tools for photoprotection — the idea being that stimulating melanin production could protect against UV-induced skin damage. Melanotan I (afamelanotide) has actually reached FDA approval: it is approved as Scenesse for the prevention of phototoxicity in adults with erythropoietic protoporphyria, a rare condition of extreme photosensitivity. Melanotan II is not FDA-approved and has a broader receptor activity profile that includes sexual arousal effects (it is the precursor to PT-141) alongside tanning effects. Both compounds are discussed in some skin contexts for tanning, but their use outside FDA-approved indications and without medical supervision carries real risks including potentially stimulating existing nevi, and they should not be treated as cosmetic skin compounds. Melanotan I's FDA approval is specific and narrow.

The peptide healing context — BPC-157, TB-500, ARA-290 — is relevant to skin in wound healing and post-procedural recovery contexts. After laser resurfacing, microneedling, surgical procedures, or significant skin injuries, the same mechanisms that make these compounds interesting for musculoskeletal repair — angiogenesis, cell migration, anti-inflammatory modulation — apply to skin tissue. BPC-157's angiogenic effects and fibroblast stimulation are relevant to wound healing in skin; TB-500's cell migration support similarly. These are not anti-aging compounds in the conventional cosmetic sense; they are being explored in the context of tissue repair and recovery from procedures.

A clear-eyed evaluation of this landscape has to acknowledge where the real effect sizes live. Daily broad-spectrum sunscreen use is the most evidence-backed intervention for preventing skin aging — UV exposure is the single largest driver of premature skin aging, and blocking it has decades of prospective data behind it. Topical retinoids (tretinoin, retinol) have among the strongest human clinical evidence of any topical intervention for skin aging, including documented effects on collagen synthesis, cell turnover, and fine lines. These are the interventions that carry the largest effect sizes, and they are available at lower cost and with more evidence than most peptide compounds discussed here.

The honest claim for topical peptides — GHK-Cu specifically, and to a lesser degree PAL-GHK and similar lipopeptides — is that they are among the better-studied add-on ingredients in skin care, with real if modest clinical evidence for effects on skin structure. The honest claim for systemic peptides is that the mechanistic logic for skin effects is often sound, the clinical evidence for skin specifically is limited, and the downstream benefits reported by patients are mostly observational. Evaluating skin peptide claims critically means asking for the evidence level: in-vitro, animal, small clinical trial, controlled study with histological endpoints? The answer varies significantly across compounds, and the landscape deserves that differentiation.

For anyone considering injectable or systemic peptide approaches with skin improvement as a goal, evaluation with a prescribing provider who can assess skin health in the context of overall physiology — hormone status, inflammatory markers, sleep, UV history — is the appropriate starting point for understanding what is actually driving skin aging in a given individual and which interventions have the most relevant mechanistic rationale.